UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): 10/08/01
----------
SANGUI BIOTECH INTERNATIONAL, INC.
(Exact name of registrant as specified in its charter)
Colorado
(State or other jurisdiction of incorporation)
0-21271 84-1330732
---------------- ------------------------
(Commission File Number) (IRS Employer Identification No.)
1508 BROOKHOLLOW DRIVE, SUITE 354
SANTA ANA, CALIFORNIA 92705
--------------------------------------------------------------------------------
(Address of principal executive offices) (Zip Code)
(714) 429-7807
-------------------------
Registrant's telephone number, including area code:
1
ITEM 6. Resignation of Registrant's Director
Sangui BioTech International, Inc. has received the resignation of Helmut Kappes
as a director of the Company and as a director of the Company's wholly-owned
subsidiary, Sangui BioTech, Inc. In July 2001, the Company filed a lawsuit
against Mr. Kappes seeking his removal as a director of the Company based on his
alleged dishonest conduct and self-dealing. The lawsuit is currently pending.
Mr. Kappes has informed the Company that he believes the allegations against him
in the lawsuit are untrue. The Company's management and Mr. Kappes also have
significant disagreements regarding the Company's unwillingness to release
confidential information, investor and shareholder relations and product
development strategies.
The Company's core competence lies in the development of highly innovative
technologies for the treatment of common illnesses such as diabetes, cancer,
stroke as well as cardiac and circulatory diseases. The Company intends to
maintain its focus on the orderly development of products in this area with an
emphasis on best serving the long-term interest of all of its shareholders.
A press release regarding the Company and Mr. Kappes was issued on October 8,
2001, a copy of which is attached hereto as Exhibit 99.1.
ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS
(c) EXHIBITS
99.1 Press Release dated October 8, 2001.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Dated: October 8, 2001 SANGUI BIOTECH INTERNATIONAL, INC.
By: /s/ Wolfgang Barnikol
----------------------------------
Wolfgang Barnikol
President & CEO
2
EXHIBIT 99.1
MONDAY, OCTOBER 8, 9:00 AM EASTERN TIME
SANGUI ANNOUNCES DIRECTOR RESIGNATION
SANTA ANA, California (October 8, 2001) Sangui BioTech International, Inc.
announced today that it has received the resignation of Helmut Kappes as a
director of the Company and as a director of the Company's wholly-owned
subsidiary, Sangui BioTech, Inc. In July 2001, the Company filed a lawsuit
against Mr. Kappes seeking his removal as a director of the Company based on his
alleged dishonest conduct and self-dealing. The lawsuit is currently pending.
Mr. Kappes has informed the Company that he believes the allegations against him
in the lawsuit are untrue. The Company's management and Mr. Kappes also have
significant disagreements regarding the Company's unwillingness to release
confidential information, investor and shareholder relations and product
development strategies.
The Company's core competence lies in the development of highly innovative
technologies for the treatment of common illnesses such as diabetes, cancer,
stroke as well as cardiac and circulatory diseases. The Company intends to
maintain its focus on the orderly development of products in this area with an
emphasis on best serving the long-term interest of all of its shareholders.
This news release includes statements, other than historical fact, that may be
deemed forward-looking. These statements may be accompanied by words such as
"believe," "estimate," "project," "expect," "anticipate," or "predict" that
conveys the uncertainty of future events or outcomes. These statements are
based on assumptions that the Company believes are reasonable; however, many
factors could cause the Company's actual results in the future to differ
materially from the forward-looking statements made herein and in any other
documents or oral presentations made by, or on behalf of, the Company.
Important factors which could cause actual results to differ materially from
those in forward-looking statements include, among others, the ability to obtain
additional financing, which is not assured; rapid technological developments and
changes; problems in developments of the Company's products; price and product
competition by competitors; general economic conditions; and factors discussed
in the Company's SEC filings.
Contact:
Sangui BioTech International, Inc.
Dr. Sieglinde Borchert, Chief Operating Officer
Borchert@sangui.de
Germany - 049 - (0)2302-915200,
Fax - 049-(0)2302-915201 or
US - 714/429-7807, Fax - 714/429-7808 or
Singapore - 0065-872-7273, Fax - 0065-873-3249
http://www.sangui.de
3